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RAPID COMMUNICATION
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Suppression of experimental crescentic glomerulonephritis by the in-
terleukin-l receptor antagonist. The role of interleukin-1 (IL-I) in the
pathogenesis of experimental crescentic glomerulonephritis was inves-
tigated. Administration of the interleukin- I receptor antagonist (IL-Ira)
was used to block the action of IL-I during disease development. Two
groups of six rats were primed with rabbit IgG, followed five days later
by injection of rabbit anti-GBM serum (day 0). Animals were treated
with a constant infusion of recombinant human IL-lra (plasma level
approximately 100 to 200 nglml) or saline (untreated) from day — I until
being killed on day 14. Untreated animals exhibited severe proteinuria
and development renal dysfunction shown by increased serum urea and
serum creatinine and reduced creatinine clearance. In contrast, IL-Ira
treated animals had significantly reduced proteinuria (IL-lra vs. un-
treated, P < 0.05) and maintained normal renal function (IL-Ira vs.
untreated, P < 0.05). Histologically, IL-ira treatment markedly re-
duced glomerular hypercellularity, glomerular necrosis and crescent
formation and almost completely abrogated tubular atrophy and fibro-
sis. IL-Ira treatment suppressed glomerular macrophage accumulation
by 57% (P < 0.01), while macrophage accumulation in the interstitium
was completely abrogated and immune activation of the interstitial T
cell infiltrate was prevented. This study demonstrates that IL-l plays a
key role in the pathogenesis of anti-GBM glomerulonephritis, and
blocking its effects may provide a novel therapeutic approach to the
treatment of human progressive glomerulonephritis.
Interleukin-l (IL-i) is an important cytokine which has a
wide range of proinflammatory and immunologic effects includ-
ing activation of endothelial cells, induction of neutrophil tissue
infiltration (via IL-8), stimulation of T and B cell activation, and
the induction of a range of other cytokines including interleu-
kins 1, 2, 6, 8, and tumor necrosis factor-a [reviewed in 1].
Activated macrophages are a major source of IL-i, although a
wide variety of cell types, including mesangial cells, can syn-
thesize IL-i [1, 2]. The demonstration that macrophage-derived
IL-l stimulated proliferation of cultured mesangial cells [3]
suggested a possible role for IL-i in mesangioproliferative
diseases. A study of patients with rapidly progressive crescen-
tic glomerulonephritis found that cultured glomeruli secreted
IL-l activity, which was attributed to the large numbers of
macrophages present within these giomeruli [4]. Glomerular
macrophage infiltration is a common feature in many forms of
human and experimental glomerulonephritis [reviewed in 51and
is probably the major source of glomerular IL-I production
reported in a wide range of experimental models of glomerulo-
nephritis including: rat focal and segmental glomerulosclerosis
[6], spontaneous murine lupus nephritis [7], rat anti-GBM
disease [8, 91, rat acute aminonucleoside nephrosis [10], and
rabbit anti-GBM disease [111. Glomerular IL-i production has
been detected during both the initiation and progressive phases
of experimental and human glomerulonephritis [4, 6—111. In
addition, pretreatment of rats with IL-i exacerbates renal injury
occurring 24 hours after injection of anti-GBM serum in terms
of increased gloinerular neutrophil accumulation and protein-
uria [12].
Production of IL-i in human and experimental disease sug-
gests, but does not prove, that this cytokine has a pathogenic
role in the induction and progression of glomerulonephritis. The
current study has addressed this question by blocking the
function of IL-i during development of accelerated anti-GBM
disease by administration of the interleukin-1 receptor antago-
nist (IL-ira). The IL-ira is a structural homologue of IL-la and
/3 which binds to IL-l receptors with an affinity equivalent to
that of IL-la and -/3, but it does not trigger cellular responses
[13—15]. The IL-ira has been shown to inhibit the effects of
recombinant IL-i both in vitro and in vivo, and the involvement
of IL-i in a number of rat models of inflammatory disease has
been demonstrated by the suppressive action of IL-lra treat-
ment [reviewed in 15]. However, the effect of IL-ira treatment
has yet to be evaluated in glomeruionephritis.
Methods
Animals
Inbred male Sprague-Dawley rats (150 g) were obtained from
the Monash University Animal House.
Nephrotoxic serum
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Rabbit anti-rat GBM nephrotoxic serum was raised by re-
peated immunization of New Zealand white rabbits with par-
ticulate rat GBM in Freund's adjuvant, as previously described
[16]. The nephrotoxic serum was pooled, decomplemented and
adsorbed extensively against normal rat erythrocytes.
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Experimental design
Passive accelerated anti-GBM disease was induced in 12 rats
by subcutaneous immunization with 5 mg normal rabbit IgG in
Freund's incomplete adjuvant, followed five days later (day 0)
by intravenous injection of 10 mI/kg body weight rabbit anti-rat
GBM serum (12.5 mg IgG/ml). One group of six rats received a
constant infusion of human recombinant IL-lra (Synergen)
from day —1 until being killed at day 14 by means of an Alzet
2002 miniosmotic pump implanted under the skin of the back
which delivered 0.5 id/hr of 50 mg/mi IL-ira in saline. The
second group of rats received saline only (untreated rats) via an
implanted pump over the same time period. Blood and 24-hour
urine collections were taken on days 1, 7, 10 and day 14. Plasma
levels of IL-ira were measured in an antibody capture ELISA
system (Synergen) with a lower sensitivity limit of 7.8 ng/mI. In
addition, one group of five normal rats was examined.
Analysis of renal function and proteinuria
Urinary protein excretion was determined using the Manual
Ponceau Red method. Concentrations of serum and urine
creatinine, and serum urea were determined using the standard
Jaffe rate reaction (alkaline picrate) or NED/OPA assay, re-
spectively. All analyses were performed in the Department of
Biochemistry, Monash Medical Centre.
Measurement of serum immuno globulins
Serum levels of rat anti-rabbit IgG and rat anti-IL-ira anti-
bodies were determined by a standard ELISA technique.
Briefly, 100 d of normal rabbit IgG or human recombinant
IL-ira (10 pg/m1 in 0.1 M carbonate-bicarbonate buffer, pH 9.0)
were bound to 96-well plates for over night at 4°C and blocked
with 100 .d of 2% bovine serum albumin in PBS for two hours
at room temperature. After the plate was washed (x 4) with
0.05% Tween 20 in PBS, dilutions of rat serum in triplicates
were added and incubated for two hours. After being washed as
above, the bound rat IgG was detected using peroxidase-
conjugated sheep anti-rat IgG (Sigma Chemical Co., St. Louis,
Missouri, USA) and developed with the OPD substrate for 10
minutes in the dark. The reaction was terminated with 3 M
H2S04 and optical density (OD) was determined at 490 nm on a
Dynatech MR5000 ELISA plate reader.
Immunofluorescence
Tissues for immunofluorescence staining were frozen in
liquid nitrogen, and cryostat sections (6 m) were stained with
fluorescein isothiocyanate (FITC)-conjugated goat anti-rat IgG,
C3 and fibrinogen or FITC-conjugated sheep anti-rabbit IgG
(Nordic, the Netherlands). Semiquantitation of rabbit IgG, rat
IgG, C3 and fibrinogen deposition in the tissue was determined
using a blinded antibody titration method. Sections from each
tissue were incubated with serial twofold dilutions of each
antibody and the titer at which antibody binding became
undectably scored. Results are expressed in terms of antibody
dilution.
Histopathology
Tissues for histology were fixed in formalin and 4 m paraffin
sections were stained with hematoxylin and eosin or periodic
acid-Schiff. To evaluate the degree of glomerular damage, the
percentage of glomeruli with lesions of atrophy; fibrinoid exu-
dation and necrosis or glomerular crescent formation was
assessed by examination of at least 100 glomeruli per animal on
hematoxylin and eosin stained sections. The degree of glomer-
ular hypercellularity was also assessed on the basis of total
glomerular cell count/glomerular cross section (gcs) and ranked
as described [171: (0), normal (less than 50 cells/gcs); (1), mild
(60 to 80 cells/gcs); (2), moderate (80 to 120 cells/gcs); (3),
severe hypercellularity (more than 120 cells/ges).
Tubulointerstitial lesions of tubular atrophy and fibrosis were
semiquantitatively analyzed on hematoxylin and eosin stained
sections and graded on a scale of 0 to 3 as previously described
[17], with modifications: (0) no apparent damage; (0.5) minor
damage, that is, lesions involving less than 5% of the cortex; (I)
mild damage, that involving 5 to 15% of the cortex; (2) moderate
damage involving 15 to 30% of the cortex; and (3) severe
damage, that is, involving more than 30% of the cortex and
focal accumulation of leukocytes at sites of damage.
The analysis of histological changes was performed blind by
an experienced renal pathologist (HYL).
Analysis of leukocyte infiltration
Tissues for immunoperoxidase staining were fixed in
paraformaldehyde-lysine-periodate and serial cryostat sections
(6 m) were labeled with monoclonal antibodies (mAbs) as
previously described [17]. Monoclonal antibodies (mAbs) used
in this study were as follows: OX-i, leukocyte common antigen
[18]; ED1, most macrophages and some dendritic cells [19];
R73, non-polymorphic a/3 T cell receptor [20]; OX- 17, MHC
class II antigen I-E epitope (RT1D) [211 (inbred Sprague-
Dawley rats do not express the MHC class II I-A epitope
recognized by the OX-6 mAb); and ART-l8, p55 chain of the rat
interleukin-2 receptor (IL-2R) [22].
Quantitation of leucocytes on tissue sections
Leukocyte subpopulations infiltrating the glomerulus and
interstitium were analyzed by mAb labeling of cryostat tissue
sections as previously described [17]. Briefly, cells labeled by
each mAb were counted in high-power fields (x 400) of 20
consecutive glomeruli for each animal. The mean of 20 glomer-
ular counts from each group of six animals was expressed as
cells standard error of mean (sEM) per glomerular cross
section. To assess tubulointerstitial leukocyte infiltration, cor-
tical areas were selected at random. The number of labeled cells
was assessed from 20 consecutive high power fields by means of
a 0.02 mm2 graticule fitted in the eyepiece of the microscope.
These fields progressed from the outer to inner cortex, avoiding
only large vessels, glomerular and immediate periglomerular
areas. For each tissue, the same area was examined in serial
sections labeled with different mAbs. No adjustment of the cell
count was made for tubules or the luminal space. The mean of
20 field counts from each group of six animals was expressed as
cells per square millimeter SEM.
Statistical analysis
Data from the measurement of renal function over the exper-
imental course was analyzed using the one way analysis of
variance (ANOVA) program from Complete Statistical System
(CSS, Statsoft, USA), and individual time points were also
compared using the unpaired t-test. Data from glomerular
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lesions and leukocytic infiltration in the two renal compart-
ments was compared using an unpaired t-test.
Results
IL-ira administration
To determine the dose of IL-ira administered by the osmotic
pumps, plasma IL-Ira levels were monitored on days 1, 7, 10,
and 14 by means of an antibody based ELISA. IL-ira treated
rats had plasma IL-ira levels (mean SEM) of 118 48, 157
21, 213 50, and 422 98 ng/mi at days 1, 7, 10, and 14,
respectively. Plasma IL-ira levels on day 14 were significantly
increased compared to all the earlier time points (P < 0.01).
There was no detectable IL-ira (<7.8 ng/ml) in plasma from
normal rats. Also, there was no detectable plasma IL-ira at the
time of pump implantation or in the saline treated rats during
the 14 day period.
Deposition of immune reactants
In untreated animals there was strong linear deposition of
rabbit IgG along the GBM. In addition, there was linear
deposition of rat IgG and C3 along the GBM, and fibrinogen was
deposited within both the glomerulus and interstitium. IL-ira
treatment made no difference to the pattern or the intensity of
deposition of rabbit IgG along the GBM as assessed by antibody
titration. Similarly, IL-ira treatment did not affect deposition of
rat IgG (mean titer 1/917 329 for IL-lra treated vs. 1/1000 for
untreated, not significant). Furthermore, serum titers of rat
anti-rabbit IgG were determined by ELISA and no difference
between IL-ira treated and untreated animals was evident
(0D490 0.366 0.02 IL-ira treated animals vs. 0D490 0.368
0.04 untreated; not significant). There was a marginal decrease
in the intensity of C3 deposition with IL-ira treatment (mean
titer 1/1133 178 for IL-Ira treated vs. 1/1640 185; not
significant).
Fibrinogen deposition was evaluated by antibody titration. In
Fig. 1. Suppression of renal injuly by IL-ira
treatment. Data for (A) 24-hour urine protein
excretion, (B) serum urea levels, (C) serum
creatinine levels, and (D) creatinine clearance
are shown. Symbols: untreated animals
(closed squares), IL-ira treated animals (open
squares), normal values (dashed line). Data is
expressed as the mean 5EM for each
experimental group, and as the mean for
normal animals. Statistical differences
between untreated and IL-lra treated groups
7 10 14 was assessed by one way analysis of variance
(ANOVA program from Complete Statistical
systems); * P < 0.05, ** P < 0.001.
normal kidney, no staining was observed with the antibody
titers used. However, there was significant fibrinogen deposi-
tion in both glomeruli and the interstitium in untreated animals
which was significantly reduced by IL-ira treatment (mean titer
1/300 25 for IL-ira treated vs. 1/640 75 untreated, P <
0.05).
In addition, infusion of the human IL-ira provoked an
antibody response to the IL-ira. Titers of anti-IL-ira in serum
at day 14 were analyzed by ELISA. There was anti-IL-ira
antibody in all six IL-ira treated animals, detectable down to a
1/200 to 1/400 dilution of serum. However, no antibody to
IL-ira was detected in the serum of saline treated animals.
Renal function and proteinuria
Untreated animals developed mild proteinuria at day 1 which
became severe from day 7 onwards (Fig. 1). Untreated animals
also exhibited renal dysfunction assessed by a significant rise in
serum urea and serum creatinine, and a fall in creatinine
clearance (Fig. I; untreated vs. normal, P < 0.01). IL-ira
treatment did not affect the initial mild proteinuria at day 1, but
it did significantly reduce proteinuria when measured on days 7,
10, and 14. Importantly, IL-ira treated animals maintained
normal renal function throughout the experimental course (Fig.
1).
Histopathology
The histologic appearance of kidneys was assessed. At the
macroscopic level, untreated rats had enlarged white kidneys
indicating gross inflammation and edema, whereas IL-Ira
treated animals had kidneys with a normal appearance and
weight (1.45 0.30 g vs. 1.09 0.13 g, P < 0.05). Microscop-
ically, glomerular and interstitial lesions apparent in untreated
rats were markedly suppressed by IL-ira treatment (Fig. 2).
Specifically, moderate to severe glomerular hypercellularity (80
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Fig. 2. Suppression of histologic lesions by IL-ira treatment. Micrographs showing hematoxylin and eosin stained 4 m paraffin kidney sections.
A. Kidney from an untreated rat at day 14 exhibiting moderate glomerular hypercellularity, crescent formation (arrow), the presence of tubular
protein casts (*), and prominent tubulointerstitial mononuclear cell infiltration with mild fibrosis. B. Kidney from an IL-ira treated at day 14 rat
showing only mild glomerular hypercellularity and minor tubulointerstitial mononuclear cell infiltration. Magnification, x250.
to 160 cells/gcs) was reduced to minor glomerular hypercellu-
larity (60 to 80 cells/gcs), glomerular necrosis was reduced (23.5
10.6% vs. 4.2 3.3% of glomeruli, P < 0.01), crescent
formation was reduced (13.0 11.2% vs. 1.2 1.6% of
glomeruli, P < 0.05), and tubular atrophy and fibrosis were
significantly reduced or completely abrogated (15 to 30% vs. 0
to 5% of tubulointerstitium).
Glomerular leukocyte infiltration
The effect of IL-ira treatment on both glomerular and inter-
stitial leukocyte accumulation was assessed by labeling cryostat
tissue sections with a panel of mAbs. Quantitation of labeled
cells is shown in Figure 3. In untreated animals there was a
large glomerular leukocytic infiltrate composed primarily of
ED1 macrophages (Fig. 3). There was also a significant
increase in the number of glomerular cells expressing MHC
class II I-E cells; these could be activated macrophages or
mesangial cells. IL-ira treatment resulted in a significant sup-
pression of the glomerular macrophage infiltrate (P <0.01), but
it did not abrogate macrophage accumulation entirely (IL-ira
vs. normal, P <0.05).
Interstitial leukocyte infiltration
In contrast to the glomerular infiltrate, the prominent inter-
stitial leukocytic infiltrate apparent in untreated animals con-
tained approximately equal numbers of ED! ÷ macrophages and
R73 T cells (Fig. 3). Many of the infiltrating T cells were
immune-activated as demonstrated by significant numbers of
IL-2R cells. The large number of I-Eq cells suggested activa-
tion of macrophages and T cells, as well as labeling interstitial
dendntic cells. IL-ira treatment had a most dramatic effect on
the interstitial leukocytic infiltrate (Fig. 3). The ED1 macro-
phage infiltrate was completely abrogated whereas the T cell
infiltrate was only partially inhibited. However, IL-ira treat-
ment prevented immune-activation of the T cell infiltrate as
evidenced by the lack of IL-2R expression. IL-Ira treatment
also significantly reduced the number of I-E cells in the
interstitium.
Discussion
This study has evaluated the effect of IL- lra treatment on the
development of anti-GBM disease in antigen primed rats—a
severe model of glomerulonephritis which exhibits many fea-
tures similar to that of rapidly progressive glomerulonephritis in
humans. IL-ira treatment suppressed the development of anti-
GBM glomerulonephritis as assessed by: (i) reduction of pro-
teinuria, (ii) prevention of renal function impairment, and (iii)
prevention of progressive histological damage including the
development of glomerular crescents. The suppression of dis-
ease development seen with targeting just one cytokine is most
impressive considering that these animals have an established
immune response to the antigen and that cyclosporin is unable
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Fig. 3. Suppression of leukocytic infiltration
and immune-activation by IL-ira treatment.
Total leukocytes and leukocyte subsets were
analyzed at day 14 by labeling tissue sections
with mAbs: OX-l, total leukocytes; ED1,
macrophages; R73, total T cells; OX-l7, MHC
class II I-E antigen; ART-18, IL-2R. A.
Quantitation of leukocyte infiltration in the
glomerulus. B. Quantitation of leukocyte
infiltration in the tubulointerstitium. Data is
expressed as the mean SEM for each group
of animals. Symbols are: (LI) normal animals;
(U) untreated animals; () IL-Ira treated
animals. Statistical differences between
normal and untreated, normal and IL-lra
treated, and untreated and IL-lra treated
groups were assessed by unpaired t-tests: *
<0.05, ** P < 0.01, P < 0.001, or not
significant (NS).
to prevent the development of anti-GBM disease in antigen
primed rats [23, 24].
Glomerular IL-I production has been demonstrated during
both the induction and progression of renal injury in experimen-
tal and human glomerulonephritis [4, 6—li], including in this
disease model [9]. This study found that IL-ira treatment had
relatively little effect upon the induction of glomerular injury
(proteinuria on day 1), but that progressive renal injury and
renal function impairment were significantly suppressed.
The suppression of anti-GBM disease by IL-ira treatment
indicates that IL-i acts at two or more levels. Firstly, IL-I is
involved in the development of the cellular immune response in
the kidney in terms of macrophage infiltration and immune-
activation of the T cell infiltrate. Secondly, IL-i may act
directly (or indirectly) upon intrinsic kidney cells as evidenced
by the reduction of glomerular hypercellularity seen with IL-ira
treatment.
The role of leukocytes in the development of accelerated
anti-GBM disease is well established and has recently been
reviewed in detail [5]. Leukocyte depletion and repletion stud-
ies and the use of anti-macrophage sera have demonstrated a
requirement for monocytes in the induction of glomerular injury
[9, 25, 26]. Hence, the partial suppression of proteinuria in this
model may be explained by the partial inhibition of glomerular
macrophage infiltration seen with IL-ira treatment. Progressive
renal function impairment in this model has been shown to
correlate very significantly with the accumulation of immune-
activated (IL-2R) mononuclear cells within the interstitium
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[17]. Thus, the complete suppression of interstitial macrophage
infiltration and the prevention of immune-activation of the
interstitial T cell infiltrate may explain the prevention interstitial
damage and renal function impairment by IL-ira treatment. The
importance of leukocyte infiltration in this disease model is
consistent with studies of human proliferative glomerulonephri-
tis in which similar glomerular leukocytic infiltration has been
described [27, 28], and the accumulation of interstitial mono-
nuclear cells has been shown to correlate significantly with the
degree of renal function impairment at the time of biopsy [27],
and to predict disease progression [29, 301.
The differential effect of IL-ira treatment upon leukocyte
infiltration in the glomerulus and the interstitium suggests that
there are two different mechanisms regulating leukocyte infil-
tration into the kidney. Deposition of rabbit IgG and rat IgG
was restricted to the GBM and absent from the interstitium.
Thus, the glomerular macrophage infiltration present in IL-Ira
treated animals may be Fe receptor mediated [31]. In this model
of anti-GBM disease, the interstitial leukocytic infiltrate ini-
tiates in the hilar region, spreads around the glomerulus, and
then becomes widespread throughout the tubulointerstitium
[17]. Cytokines such as IL-i or those induced by IL-l may be
produced within the glomerulus and then diffuse down the
mesangial stalk to the hilar region and induce macrophage
infiltration from nearby capillaries via induction of endothelial
expression of leukocyte adhesion molecules or by promoting
macrophage movement from the mesangium to the hilar region
by a direct or indirect chemotaxis mechanism [321. The postu-
late of IL-I driven macrophage infiltration is supported by in
vitro studies showing that culture of normal glomeruli with
IL-la induces expression of mRNA for IL-i/3 [33] and for
leukocyte adhesion molecules VCAM-l and ELAM-l [51.
One prominent effect of IL-ira treatment in this model was
the suppression of mesangial cell proliferation as evidenced by
the reduction of mesangial hypercellularity well beyond that
accounted for by the partial reduction of glomerular macro-
phage infiltration. This is consistent with a role for IL-i in
mesangial cell proliferation. However, the IL-ira mediated
suppression of mesangial cell proliferation could also operate
indirectly by preventing the IL- 1 dependent production of other
mesangial cell growth factors such as IL-6.
IL-lra treatment caused significant suppression of the cell-
mediated immune response within the kidney, but IL-ira treat-
ment did not inhibit the systemic humoral immune response in
terms of production of anti-rabbit IgG antibody and the depo-
sition of rat IgG along the GBM. In addition, animals treated
with the IL-ira developed antibodies to the antagonist. This is
consistent with a recent study demonstrating that IL-ira does
not inhibit antigen-specific immune responses in vivo [34].
Hence, IL-ira inhibition of progressive renal injury in this
model is not due to general immune suppression.
In summary, this is the first study to demonstrate a patho-
genic role for the cytokine IL-i in the development of experi-
mental glomerulonephritis. The ability to target one cytokine
and produce such profound effects upon disease development
suggests that cytokines operate in an interdependent fashion
rather than their often overlapping effects allowing room for
redundancy within the cytokine response. The very marked
effects of IL-ira treatment on the development and immune-
activation of the interstitial leukocytic infiltrate argues that
further studies are warranted to assess whether this drug—
which has thus far no detectable side effects—has therapeutic
potential for the treatment of proliferative glomerulonephritis.
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